Information about Dapagliflozin
Dapagliflozin (cap' a gli floe' zin) is a specific SGLT-2 inhibitor that has been shown to result in a reduction in serum HgbA1c levels and better control of type 2 diabetes, both as monotherapy (in patients who failed to achieve adequate glycemic control on diet and exercise) or in combination with insulin, metformin and or sulfonylureas.
FDA approval information for Dapagliflozin
Dapagliflozin was approved for use in the United States in 2014 and current indications are for management of hyperglycemia in patients with type 2 diabetes in conjunction with diet and exercise with or without other antidiabetic medications.
Dosage and administration for Dapagliflozin
Dapagliflozin is available in tablets of 5 and 10 mg under the brand name Farxiga, the recommended dose being 5 to 10 mg once daily. Fixed extended release combinations of dapaglifozin with metformin are also available (Zigduo XR).
Side effects of Dapagliflozin
Common side effects include symptoms of thirst, urinary tract infections and mycotic genital infections. Less common side effects are hypoglycemia, dehydration, hypovolemia and serum cholesterol and creatinine elevations.
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors